Disease-modifying trials in Alzheimer's disease: a European task force consensus

Area of Science:

• Neuroscience
• Clinical Trials
• Pharmacology

Background:

• Current Alzheimer's disease (AD) treatments primarily focus on symptom management.
• The development of disease-modifying therapies (DMTs) represents the next frontier in AD therapeutics.
• Significant challenges and controversies exist regarding the design and implementation of DMT trials.

Purpose of the Study:

• To establish a European consensus on the principles and methodologies for conducting disease-modifying trials in Alzheimer's disease.
• To address key questions surrounding patient selection, trial duration, endpoints, and the use of biomarkers.
• To provide a unified European perspective on disease modification strategies in AD.

Main Methods:

• A consensus-building process involving experts under the European Alzheimer's Disease Consortium.
• Discussion and agreement on critical aspects of AD DMT trial design.
• Consideration of European perspectives on disease modification, study design, biomarkers, risk-benefit analysis, and pharmacoeconomics.

Main Results:

• The consensus outlines key considerations for designing effective Alzheimer's disease clinical trials.
• It addresses the selection of appropriate patient populations and optimal trial durations.
• The role and utility of biomarkers, alongside risk-benefit and economic factors, are discussed.

Conclusions:

• A consensus has been reached on crucial elements for advancing disease-modifying drug development in Alzheimer's disease.
• The presented framework guides future clinical trial design, aiming for more effective therapeutic strategies.
• This European perspective emphasizes a comprehensive approach, integrating scientific, clinical, and economic considerations.